Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

As the number of patients with Alzheimer's disease (AD) increases, it brings great suffering
to their families and causes a heavy socioeconomic burden to society. A vast amount of …

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease
and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Neuronal cell loss is a defining feature of Alzheimer's disease (AD), but the underlying
mechanisms remain unclear. We xenografted human or mouse neurons into the brain of a …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …

Alzheimer's disease (AD) is the consequence of neuronal death and brain atrophy
associated with the aggregation of protein tau into fibrils. Thus disaggregation of tau fibrils …

Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

The functions of the neuronal microtubule-associated protein Tau in the central nervous
system are regulated by manifold posttranslational modifications at more than 50 sites. Tau …